Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)

Trial Profile

A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Pritelivir (Primary) ; Foscarnet
  • Indications Herpes simplex virus infections
  • Focus Therapeutic Use
  • Acronyms PRIOH-1
  • Sponsors AiCuris
  • Most Recent Events

    • 16 Nov 2018 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.
    • 16 Nov 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Aug 2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top